Bleeding Disorders

Bleeding Disorders

A collection of features and news articles published in ASH Clinical News related to bleeding disorders.

FDA Approves New Hemophilia A Treatment

The U.S. Food and Drug Administration (FDA) approved turoctocog alfa pegol, formerly known as N8-GP, for the treatment of children and adults with hemophilia...

Caplacizumab Improves Platelet Normalization Time, Reduces Mortality in Acquired TTP

Adding caplacizumab to standard of care for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) shortened the time to the normalization of platelet counts...

Roche Will Donate Hemophilia A Drug to Developing Countries

Roche will donate its new hemophilia A drug emicizumab-kxwh to the World Hemophilia Federation (WHF) Humanitarian Aid Program. Roche joins other companies – including...

New Drug Approvals in Nonmalignant Hematology

In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications...

China First to Approve Oral Drug to Stimulate Erythropoiesis

China’s National Medical Products Administration approved the oral anemia drug roxadustat, well before regulators in the U.S. or Europe have issued decisions. The hypoxia-inducible...

FDA Approves New Hemophilia A Drug

The FDA has approved emicizumab-kxwh as prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A...

Emicizumab Prophylaxis Reduces Bleeding Events in Hemophilia A Without Inhibitors

Treatment with emicizumab was associated with lower bleeding rates, compared with no prophylaxis, in patients with hemophilia A without inhibitors, according to findings from...

No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...

Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...

FDA Approves New Treatment for Hemophilia

The U.S. Food and Drug Administration (FDA) approved BAY94-9027, or antihemophilic factor (recombinant), PEGylated-aucl, for the prophylactic treatment of adults and adolescents (≥12 years)...

Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis

Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.